We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| TSXV:MOM | TSX Venture | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0 | - |
From Sep 2019 to Sep 2024
WINNIPEG, MANITOBA--(Marketwired - May 29, 2014) - Miraculins Inc. (TSX-VENTURE:MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that at today's annual and special meeting of shareholders (the "Meeting"), Harry Bloomfield, Christopher Moreau, William Roberts and Michael Stasiuk were reelected as directors of the Company to hold office until the next annual meeting of shareholders, or until their successors are duly elected or appointed. James Mellon had advised the Company prior to the Meeting that he would not be standing for reelection.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Miraculins Inc.Christopher J. MoreauPresident & CEO204-477-7599204-453-1546info@miraculins.comwww.miraculins.com
1 Year Miraculins Inc. Chart |
1 Month Miraculins Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
